FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
The regulatory body granted accelerated approval to linvoseltamab under the brand name Lynozyfic for the treatment of R/R MM who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti CD38 monoclonal antibody.
Lynozyfic is a fully human BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on MM cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing.
Year to date, REGN's shares have lost 22.9% compared with the industry's 0.6% decline.
Image Source: Zacks Investment Research
The approval was based on positive results from the phase I/II LINKER-MM1 trial, wherein Lynozyfic demonstrated one of the highest objective response rates (70%) and complete response rates (45%) among bispecific antibodies for this challenging patient population.
With the FDA approval, Lynozyfic is the first FDA-approved BCMAxCD3 bispecific antibody that can be dosed every two weeks starting at week 14, and every four weeks if a very good partial response (VGPR) or better is achieved following completion of at least 24 weeks of therapy.
MM remains the second most common blood cancer, with more than 36,000 new cases expected in the US in 2025 alone.Lynozyfic is tailored for patients who have undergone at least four prior treatment regimens, addressing a critical unmet need in late-stage MM.
The approval strengthens REGN's oncology portfolio.
Lynozyfic is also approved in the European Union to treat adults with R/R MM after at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
We note that the FDA had earlier issued a CRL for the BLA for linvoseltamab in R/R multiple myeloma. The sole approvability issue identified was related to findings from a pre-approval inspection at a third-party fill/finish manufacturer.
Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote
REGN is currently looking to strengthen its oncology franchise, which currently comprises Libtayo, indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma and advanced non-small cell lung cancer.
REGN's oncology franchise received a boost with the European Commission's approval of odronextamab in 2024 for treating adult patients with R/R follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The drug has been approved under the brand name Ordspono.
However, the company's efforts to get odronextamab approved in the United States suffered a setback. The regulatory body issued CRLs for its BLA for odronextamab in 2024.
The FDA has accepted for review the resubmission of the BLA for odronextamab in R/R follicular lymphoma with a target action date of July 30, 2025.
The successful development of these oncology drugs should be a great boost for REGN.
The decline in lead drug Eylea sales is a concern for REGN.
Eylea sales are under pressure due to competition from Roche's RHHBY Vabysmo. Roche designed Vabysmo to block pathways involving Ang-2 and VEGF-A.
The uptake of Vabysmo has been outstanding, causing a loss of market share for Eylea.
REGN currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis NVS and Bayer BAYRY, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.69 to $8.81 over the past 60 days. EPS estimates for 2026 have jumped 12 cents to $9.12 during this time frame. The stock has risen 30.2% so far this year.
BAYRY's 2025 EPS estimate has increased from $1.19 to $1.25 over the past 90 days, while that for 2026 has gone up from $1.28 to $1.31 over the same time frame. Year to date, shares of Bayer have surged 60%.
BAYRY's earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
Novartis AG (NVS) : Free Stock Analysis Report
Roche Holding AG (RHHBY) : Free Stock Analysis Report
Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Tempus AI (TEM) Raises Full-Year Revenue Guidance
Tempus AI has posted an impressive price move of 21% over the last week, likely influenced by a blend of recent developments. The company announced significant revenue growth in its second quarter results and notably reduced its net loss. This positive financial performance was reinforced by the raised full-year revenue guidance, although it accompanies challenges such as a class action lawsuit and a substantial equity offering. The broader market has also been on an upward trajectory, with the Dow reaching records, which may have contributed to buoying Tempus AI's stock amidst mixed news on legal and financial fronts. We've discovered 3 warning signs for Tempus AI that you should be aware of before investing here. We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Tempus AI's recent developments, including significant revenue growth and reduced net loss for the second quarter, have influenced its impressive 21% share price increase over the last week. Over the longer period of the past year, the company's total return was 45.01%, showcasing substantial growth compared to both the broader market and its industry peers. Tempus AI outpaced the US Life Sciences industry, which had a return of -19.8%, and also exceeded the US market's 17% return. These positive financial results reinforce the company's revenue and earnings forecasts, supported by strong testing volumes and strategic biopharma partnerships. Analysts have projected Tempus AI's revenue to grow by 29.8% annually over the next three years, even though profitability remains elusive in the short term. The raised full-year revenue guidance could further bolster future earnings, provided reimbursement and regulatory challenges are effectively managed. Despite the current share price of $73.78, slightly above the consensus analyst price target of $70.0, the company's rapid growth trajectory potentially justifies this premium. Analysts' expectations reflect a degree of agreement regarding Tempus AI's valuation, suggesting that the stock may be fairly priced. However, sustained momentum in revenue, coupled with disciplined cost management, will be crucial for aligning with long-term growth objectives and closing any gaps between market performance and valuation targets. Our comprehensive valuation report raises the possibility that Tempus AI is priced higher than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include TEM. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Anxiety Builds at CBS News Over Potential Moves by Skydance
The journalists at CBS News are eager to report out details of what might happen to their own workplace. Staffers at the unit, now part of Paramount Skydance, are worried about the potential for a new round of layoffs, according to three people familiar with the news division, and are also curious about a possible new chapter for 'CBS Evening News,' which has seen its ratings drop noticeably since embracing a new, atypical format. More from Variety 'CBS Evening News' Executive Producer Guy Campanile to Return to '60 Minutes' Paramount Skydance Shares End Roller-Coaster, Memestock-Fueled Week Up 30%, Boosting Market Cap by $2 Billion Investor Mario Gabelli Sues Shari Redstone's National Amusements Inc. Alleging 'Unfair and Inequitable' Terms in Paramount-Skydance Merger CBS News declined to make executives available for comment. Layoffs are indeed possible. Executives from Skydance signaled earlier this month during a meeting with reporters that they intended to follow through on previously announced plans to cut $2 billion in costs from the company, which has suffered from longer-term downturns in traditional advertising and distribution revenue as one-time TV viewers embrace streaming technology. Jeff Shell, the new president of Skydance, indicated those cuts and reductions should be disclosed by the company's next quarterly report to investors in November. As for 'CBS Evening News,' executives are poised to experiment with a tweak to the current format, which relies on two anchors delivering news side by side. A person familiar with the matter suggests viewers will in weeks to come see a more frequent reliance on one of the anchors — John Dickerson and Maurice DuBois lead the program — being out on the road at major, breaking events. Just last week, Dickerson was on the ground in Alaska as U.S. President Donald Trump and Russian President Vladimir Putin met to discuss Russia's ongoing battle with Ukraine. Making use of both anchors in such fashion would put an authoritative person in the field and the studio, this person suggested, while giving the newscast the ability to deliver breaking news at the top of the broadcast. That suggests a new wrinkle in the show's mission. The original concept behind this 'Evening News' iteration was to emphasize more feature and enterprise reporting. In its earliest weeks, even CBS News' Washington bureau veterans tried to examine the effects of Trump-era policies on people in places like Baltimore or Canada. And yet, critics complained that the show was at times giving short shrift to breaking headlines. The format tweak could potentially give 'Evening News' a shot of the latest headlines while still leaving some room for the distinct elements it brings to the mix. Speculation on 'Evening News' has grown since the disclosure that its current executive producer, Guy Campanile, would leave the show and return to his former home, '60 Minutes,' where he has long worked as a producer. One of the concepts behind the new 'Evening News' was to adopt some of the spirit of '60,' which generates its own headlines by pursuing stories both tied to headlines and completely disconnected from them. But evening-news audiences, accustomed to a format that has worn well for many decades, didn't bite. Approximately 3.74 million viewers watched 'CBS Evening News' for the five-day period ended August 4, according to Nielsen. ABC's 'World News Tonight,' which leads the category, captured an average of nearly 6.89 million, while NBC's 'NBC Nightly News' won an average of nearly 5.35 million. CBS News executives had hoped their new 'Evening News' might pick up viewers as Tom Llamas picked up the reins at NBC following a decision by Lester Holt to step away from the 'Nightly' role. Instead, the CBS show has lost hundreds of thousands of viewers since moving away from the format that had been anchored by Norah O'Donnell. One potential candidate to take the 'Evening News' reins behind the camera is said to be Kim Harvey, a veteran producer who has worked for CNN, Fox News Channel and MSNBC, along with CBS News. Harvey has logged time working on MSNBC town halls during the run up to the 2016 election, and with anchors that range from Rachel Maddow and Chris Hayes to Bill O'Reilly and Greta Van Susteren. Best of Variety New Movies Out Now in Theaters: What to See This Week What's Coming to Disney+ in August 2025 What's Coming to Netflix in August 2025
Yahoo
19 minutes ago
- Yahoo
After heart surgery, flag football champ Sophie Guitron is chasing L.A. Olympics bid
At age 10, Sophie Guitron began to suspect that something was wrong. For two weeks, her high fever and rashes did not respond to any treatment. 'I went to the hospital and they couldn't find what was wrong with me. I had very high fevers, rashes all over my body and nothing controlled the symptoms,' Guitron recalled. She was initially diagnosed with arthritis, but after a series of tests, doctors detected something much more serious: a rare congenital heart disease that required open-heart surgery. 'The final diagnosis was systemic juvenile idiopathic arthritis. Instead of my joints becoming inflamed, my organs were inflamed, and that's how they discovered the heart disease I was born with,' explained the Mira Costa High graduate. Guitron was born with an anomaly in the aortic portion of the left coronary artery, an extremely rare condition. Read more: L.A. names coveted five provisional sports it wants to add for 2028 Olympics Her father, José, recalls that despite the pain, his daughter never lost her composure. 'She has always had a very high pain tolerance,' he said. In August 2018, Sophie Guitron underwent successful surgery at Stanford Hospital in Palo Alto. Although her recovery was long and emotionally difficult, especially because she couldn't immediately return to soccer, her sport since the age of 6, that moment marked the beginning of a new chapter. During school breaks, while watching her classmates play flag football, something awakened in her. She learned the rules, decided to give it a try and fell in love with this new sport. She joined a recreational team and won a championship in a local league, as well as the respect of her teammates, being the only girl on the team. The title was especially meaningful: Guitron scored the winning touchdown and was named most valuable player of the tournament. With her passion for this new sport growing, she joined a co-ed club where she continued to develop. In high school, she realized that Mira Costa did not have a women's team. So she wrote directly to the Chargers for help. The NFL franchise responded by sponsoring the creation of the first women's flag football team in the school's history. The effort paid off. During her senior year, Guitron and Mira Costa won the Bay League championship and achieved the school's first playoff victory. Playing various positions, but excelling mainly as a wide receiver, Guitron was recognized as the league's most valuable player and received Division 2 All-CIF honors. Her development was partly thanks to the Conquer Chargers club in Irvine. Her parents supported her by driving her to practice, a trip that took more than an hour each way to and from Orange County. Guitron's Conquer Chargers coach, Justin Schulman, highlighted not only her skill but also her mindset: 'She knew what she wanted, she sought us out on social media, and she earned her spot. She's a very talented runner, but above all, she's determined.' In 2024, she represented the United States in the Junior International Flag Football Cup, winning the gold medal against teams from Canada, Japan, Panama and Mexico. Her growth did not go unnoticed. The NFL recently chose her to be part of the 'Chase Something' campaign, alongside quarterback Jayden Daniels and Olympic gymnast Jordan Chiles. The campaign urges young athletes to pursue their dreams. She had previously been awarded the NFL Latino Youth Honors 2024 in New Orleans, an event that celebrates Latino seniors with athletic and academic achievements. With a 4.2 GPA and nominated by the Rams, she received $25,000 for her college education. Guitron, 18, will play flag football for Keiser University in Florida, alongside other emerging stars of the sport such as Janasia Wilson and Ashlea Klam. She plans to study sports management and has already represented the United States at the U17 level. But her biggest dream is clear: to make it to the 2028 Los Angeles Olympics, where flag football will make its debut in the Olympic program. 'I'm working very hard to be at the 2028 Games, but my career won't end there. I'm young and I also want to make it to the 2032 Olympics,' said Guitron, who is 5-foot-5. Schulman, Guitron's coach, says there is no doubt that she will succeed. 'She is so dedicated to the sport," he said. "... I've already asked her to save me tickets to see her in Los Angeles.' With deep Latino roots, the daughter of Lilia, born in Mexico, and José, a Californian with Mexican parents, Guitron is also aware she is a role model. 'I am proud to be American, but also Mexican American. It is an honor to represent Latinas in sports. I love being that person,' Guitron said. Her father agrees: 'I remind her that she is a pioneer. She is part of a movement that, in the future, will be history.' Although her arthritis is still present, in remission but with occasional flares of pain, Guitron believes that her experiences have made her stronger. 'I am very grateful for everything I have been through, even though it has been difficult," Guitron said. "It has made me who I am." This article first appeared in Spanish via L.A. Times en Español. Get the best, most interesting and strangest stories of the day from the L.A. sports scene and beyond from our newsletter The Sports Report. This story originally appeared in Los Angeles Times.
